Blockbuster 'K-Cap' Challenge to Solve Patents has begun
Blockbuster 'K-Cap' Challenge to Solve Patents has begun
  • Cho Pil Hyun, Staff Reporter
  • 승인 2024.03.06 14:03
  • 수정 2024.03.06 14:03
  • 댓글 0
이 기사를 공유합니다

The new P-CAB family of gastroesophageal reflux disease treatment for K-CAB, the 30th new domestic drug, is K-CAB. Since its launch in 2019, it has recorded growth every year, boasting more than 100 billion won in annual sales.

It has been on a roll, recording accumulated sales of 478.8 billion won in the first 10 months of last year.

It's literally a 'blockbuster' product.

It seems that a strong challenge is starting for this K-cap. Several domestic pharmaceutical companies have begun to compete in related markets, including the Patent Tribunal's request to release K-cap patents.

According to the pharmaceutical industry on the 5th, more than 60 domestic pharmaceutical companies, including Tama Pharmaceutical and Samcheondang Pharmaceutical, won some of the K-Cap passive rights confirmation trials filed with the Patent Tribunal.

K-Cap has three major patents.

These include crystalline patents and use patents that expire in 2036, and material patents that expire in 2031.

In the lawsuit, Hae-hae Pharmaceutical and Samcheondang Pharmaceutical won some of the decisive patents that expire in 2036.

In this regard, attention is being paid to what position HK Innoen, who holds the K-cap, will present.

Meanwhile, HK Innoen is jointly selling K-cap with Boryeong this year.

The two companies recently signed a domestic joint sales and marketing contract for representative items K-Cap and Kanab.

Kwak Dal-won, president of HK Innoen, said, "The cooperation between the two companies that created the new blockbuster drug is a new attempt that has been hard to find.“

[WIKI KOREA=Cho Pil Hyun, Staff Reporter]

chop23@wikileaks-kr.org

기자가 쓴 기사

  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2024 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 : laputa813@wikileaks-kr.org
ND소프트